Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications

Differences in cutaneous melanoma survival between the 7th and 8th edition of the American Joint Committee on Cancer (AJCC). A multicentric population-based study

(2021) Alicia Barreiro-Capurro et al.   EUROPEAN JOURNAL OF CANCER

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

(2021) E. A. Rozeman et al.   NATURE MEDICINE

Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response

(2021) Fabio Valenti et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation–positive melanoma receiving adjuvant vemurafenib

(2020) P.A. Ascierto et al.   ANNALS OF ONCOLOGY

Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells

(2020) Carlos Alberto Aya-Bonilla et al.   BRITISH JOURNAL OF CANCER

Circulating Tumor Cells and Early Relapse in Node-positive Melanoma

(2020) Anthony Lucci et al.   CLINICAL CANCER RESEARCH

BRAF V600E mutation as a prognostic factor in cutaneous melanoma patients

(2020) Faruk Tas et al.   Dermatologic Therapy

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial

(2020) Reinhard Dummer et al.   LANCET ONCOLOGY

Tumour-infiltrating lymphocyte and histological regression in primary melanoma

(2020) Simone Ribero et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Radiomics, tumor volume and blood biomarkers for early prediction of pseudoprogression in metastatic melanoma patients treated with immune checkpoint inhibition

(2020) Lucas Basler et al.   CLINICAL CANCER RESEARCH

Defining the Prognostic Role of MicroRNAs in Cutaneous Melanoma

(2020) Emi Dika et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Virtual biopsy using MRI radiomics for prediction of BRAF status in melanoma brain metastasis

(2020) Ben Shofty et al.   Scientific Reports

Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma

(2020) Magali Boyer et al.   Cancers

Microenvironment in cutaneous melanomas: a gene expression profile study may explain the role of histological regression

(2020) S. Osella‐Abate et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

1131P C-reactive protein as biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting

(2020) J. Lauwyck et al.   ANNALS OF ONCOLOGY

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

(2020) Alexander M. M. Eggermont et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

(2020) Paolo A Ascierto et al.   LANCET ONCOLOGY

Isolation of extracellular vesicles improves the detection of mutant DNA from plasma of metastatic melanoma patients

(2020) Davide Zocco et al.   Scientific Reports

Circulating tumour DNA and melanoma survival: A systematic literature review and meta-analysis

(2020) Sara Gandini et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Correlating Radiomic Features of Heterogeneity on CT with Circulating Tumor DNA in Metastatic Melanoma

(2020) Andrew B Gill et al.   Cancers

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA

(2019) L Tan et al.   ANNALS OF ONCOLOGY

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients

(2019) J H Lee et al.   ANNALS OF ONCOLOGY

Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAFV600E mutation

(2019) Susana García-Silva et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A Brief Communication on Circulating PD-1-positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy With Nivolumab

(2019) Thilo Gambichler et al.   JOURNAL OF IMMUNOTHERAPY

Phenotypic characterisation of immune cells associated with histological regression in cutaneous melanoma

(2019) Simona Osella-Abate et al.   PATHOLOGY

Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy

(2019) Selena Y. Lin et al.   CLINICAL CHEMISTRY

Circulating mi RNA expression analysis reveals new potential biomarkers for human cutaneous melanoma staging

(2019) B. Sánchez‐Sendra et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

(2019) Nikolaus B. Wagner et al.   Journal for ImmunoTherapy of Cancer

Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients

(2018) Jonathan S. Zager et al.   BMC CANCER

Melanoma circulating tumor cells: Benefits and challenges required for clinical application

(2018) G. Marsavela et al.   CANCER LETTERS

The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care

(2018) Emily Z. Keung et al.   Expert Review of Anticancer Therapy

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

(2018) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gene Expression Detection Assay for Cancer Clinical Use

(2018) Shavira Narrandes et al.   Journal of Cancer

Melanoma

(2018) Dirk Schadendorf et al.   LANCET

Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma

(2018) Veronica Huber et al.   JOURNAL OF CLINICAL INVESTIGATION

Role of interferon in melanoma: old hopes and new perspectives

(2017) Martina Sanlorenzo et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective

(2017) Mathilde Postel et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients

(2017) Stefano Guadagni et al.   MELANOMA RESEARCH

A non-coding function of TYRP1 mRNA promotes melanoma growth

(2017) David Gilot et al.   NATURE CELL BIOLOGY

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

(2017) Jeffrey Weber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

(2017) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities

(2017) Goran Micevic et al.   Clinical Epigenetics

Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma

(2016) S. Ekmekcioglu et al.   CLINICAL CANCER RESEARCH

PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma

(2016) J. Madore et al.   CLINICAL CANCER RESEARCH

What Is New in Melanoma Genetics and Treatment?

(2016) Simone Ribero et al.   DERMATOLOGY

Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB–III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity

(2016) Alexander M.M. Eggermont et al.   EUROPEAN JOURNAL OF CANCER

Liquid biopsy: Potential and challenges

(2016) Klaus Pantel et al.   Molecular Oncology

miR-579-3p controls melanoma progression and resistance to target therapy

(2016) Luigi Fattore et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MicroRNA dysregulation in melanoma

(2016) Nicholas Latchana et al.   SURGICAL ONCOLOGY-OXFORD

Socioeconomic and lifestyle factors and melanoma: a systematic review

(2015) A.J. Jiang et al.   BRITISH JOURNAL OF DERMATOLOGY

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

(2015) Sonja Kleffel et al.   CELL

Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy

(2015) Pedram Gerami et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection

(2014) M. Picard et al.   BRITISH JOURNAL OF DERMATOLOGY

BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: Implications for melanoma staging and adjuvant therapy

(2014) Andrew P. Barbour et al.   EUROPEAN JOURNAL OF CANCER

Nonsentinel Lymph Node Status in Patients With Cutaneous Melanoma: Results From a Multi-Institution Prognostic Study

(2014) Sandro Pasquali et al.   JOURNAL OF CLINICAL ONCOLOGY

Liquid Biopsies: Genotyping Circulating Tumor DNA

(2014) Luis A. Diaz et al.   JOURNAL OF CLINICAL ONCOLOGY

Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients

(2014) Swetlana Mactier et al.   Pigment Cell & Melanoma Research

Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients

(2013) P El Hajj et al.   BRITISH JOURNAL OF CANCER

Prognostic Value of BRAF V600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes

(2012) Stéphanie Moreau et al.   ANNALS OF SURGICAL ONCOLOGY

Association Between Circulating Tumor Cells and Prognosis in Patients With Stage III Melanoma With Sentinel Lymph Node Metastasis in a Phase III International Multicenter Trial

(2012) Sojun Hoshimoto et al.   JOURNAL OF CLINICAL ONCOLOGY

AIM1 and LINE-1 Epigenetic Aberrations in Tumor and Serum Relate to Melanoma Progression and Disease Outcome

(2012) Sojun Hoshimoto et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma

(2012) Graham J. Mann et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients

(2012) Luca Sigalotti et al.   Journal of Translational Medicine

The role of BRAF V600 mutation in melanoma

(2012) Paolo A Ascierto et al.   Journal of Translational Medicine

Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma

(2012) Molly Yancovitz et al.   PLoS One

TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome

(2011) F Journe et al.   BRITISH JOURNAL OF CANCER

Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients

(2011) Luca Sigalotti et al.   Journal of Translational Medicine

Raf kinases in cancer–roles and therapeutic opportunities

(2011) G Maurer et al.   ONCOGENE

Melanoma MicroRNA Signature Predicts Post-Recurrence Survival

(2010) M. F. Segura et al.   CLINICAL CANCER RESEARCH

CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma

(2009) A. Tanemura et al.   CLINICAL CANCER RESEARCH

Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival

(2009) D. Bogunovic et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma

(2008) T. John et al.   CLINICAL CANCER RESEARCH

Prognostic versus predictive value of biomarkers in oncology

(2008) C.N.A.M. Oldenhuis et al.   EUROPEAN JOURNAL OF CANCER